Epratuzumab phase IIb data presented at ACR show pipeline drug had positive effect in patients suffering from moderate to severe systemic lupus erythematosus
New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations with Active Rheumatoid Arthritis (RA)